Cardiovascular diseases (CVD) & Drugs/Treatments

Only people at high and very high risk of cardiovascular events benefit from combination treatment with statins + ezetimibe and/or Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

Fewer non-fatal myocardial infarctions and strokes occur with the combination treatment; according to current knowledge, survival will not be extended.

We consider potential therapeutic strategies targeting the intestinal microbiota to influence the susceptibility and progression of Cardiovascular Diseases (CVD)
Tang et al. 2019a Nat Rev Cardiol. 16(3): 137-154

Novel therapeutic strategies targeting microbial metabolic pathways and/or metabolites, as well as altering microbial composition, have the potential to modulate cardiovascular disease susceptibility and prevent progression to heart failure
Tang et al. 2019a Nat Rev Cardiol. 16(3): 137-154